In vitro testing of thiolated poly(Aspartic acid) from ophthalmic formulation aspects

Drug Development and Industrial Pharmacy

Volumn 42, Issue 8, 2015, Pages 1241-1246

  Budai Szücs, Mária ^a   Horvát, Gabriella ^a   Gyarmati, Benjámin ^b   Szilágyi, Barnabás Á Ron ^b   Szilágyi, András ^b   Csihi, Tímea ^a   Berkó, Szilvia ^a   Szabó Révész, Piroska ^a   Mori, Michela ^c   Sandri, Giuseppina ^c   Bonferoni, Maria Cristina ^c   Caramella, Carla ^c   Csányi, Erzsébet ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cytotoxicity; Mucoadhesion; Ocular drug delivery; Pharmaceutical preformulation; Rheology; Thiolated polymer

Indexed keywords

AGENTS ACTING ON THE EYE; NANOCARRIER; POLYASPARTIC ACID; THIOLATED POLY(ASPARTIC ACID); UNCLASSIFIED DRUG; ASPARTIC ACID; DRUG CARRIER; EYE DROPS; GEL; POLYMER; THIOL DERIVATIVE;

ARTICLE; CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EYE TOXICITY; FLOW KINETICS; IN VITRO STUDY; OSMOLALITY; PH MEASUREMENT; PHYSICAL CHEMISTRY; REFRACTION INDEX; SURFACE TENSION; ADHESION; ANIMAL; BIOAVAILABILITY; CELL LINE; CHEMISTRY; EYE; GEL; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES; RABBIT;

ADHESIVENESS; ANIMALS; ASPARTIC ACID; BIOLOGICAL AVAILABILITY; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EYE; GELS; OPHTHALMIC SOLUTIONS; POLYMERS; RABBITS; RHEOLOGY; SULFHYDRYL COMPOUNDS;

EID: 84985001703     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2015.1118497     Document Type: Article

References (46)

1. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005;57:1595-639.
2. Lorentz H, Sheardown H. Ocular delivery of biopharmaceuticals. In: Neves J, Sarmento B, eds. Mucosal delivery of biopharmaceuticals: biology, challenges and strategies. New York (NY): Springer; 2014:221-59.
3. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006;58:1131-5.
4. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv 2006;3:275-87.
5. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol 1993;37:435-56.
6. Baeyens V, Gurny R. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv 1997;72:191-202.
7. Gavini E, Bonferoni MC, Rassu G, et al. Engineered microparticles based on drug-polymer coprecipitates for ocularcontrolled delivery of Ciprofloxacin: influence of technological parameters. Drug Dev Ind Pharm 2015 [Epub ahead of print]. doi: 10.3109/03639045.2015.1100201.
8. Üstündaǧ-Okur N, Gökçe EH, Bozbıyık DI, et al. Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis. Expert Opin Drug Deliv 2015;12:1791-807.
9. Fabiano A, Chetoni P, Zambito Y. Mucoadhesive nano-sized supramolecular assemblies for improved pre-corneal drug residence time. Drug Dev Ind Pharm 2015;41:2069-76.
10. Nasr FH, Khoee S. Design, characterization and in vitro evaluation of novel shell crosslinked poly(butylene adipate)- co-N-succinyl chitosan nanogels containing loteprednol etabonate: a new system for therapeutic effect enhancement via controlled drug delivery. Eur J Med Chem 2015;102:132-42.
11. Chhonker YS, Prasad YD, Chandasana H, et al. Amphotericin-B entrapped lecithin/chitosan nanoparticles for prolonged ocular application. Int J Biol Macromol 2015;72:1451-8.
12. Horvát G, Budai-Szücs M, Berkó S, et al. Comparative study of nanosized cross-linked sodium-, linear sodium- and zinchyaluronate as potential ocular mucoadhesive drug delivery systems. Int J Pharm 2015;494:321-8.
13. Fernández-Ferreiro A, González Barcia M, Gil-Martínez M, et al. In vitro and in vivo ocular safety and eye surface permanence determination by direct and Magnetic Resonance Imaging of ion-sensitive hydrogels based on gellan gum and kappa-carrageenan. Eur J Pharm Biopharm 2015;94:342-51.
14. Abdelkader H, Pierscionek B, Alany RG. Novel in situ gelling ocular films for the opioid growth factor-receptor antagonistnaltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies. Int J Pharm 2014;477:631-42.
15. Makwana SB, Patel VA, Parmar SJ. Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride. Results Pharma Sci. [Epub ahead of print]. doi:10.1016/j.rinphs.2015.06.001.
16. Horvát G, Gyarmati B, BerkóS, et al. Thiolated poly(aspartic acid) as potential in situ gelling, ocular mucoadhesive drug delivery system. Eur J Pharm Sci 2015;67:1-11.
17. Ahmed I, Gokhale RD, Shah MV, Patton TF. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J Pharm Sci 1987;76:583-6.
18. Sasaki H, Igarashi Y, Nagano T, et al. Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Pharm Res 1995;12:1146-50.
19. Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular drug delivery. J Drug Target 2004;12:623-33.
20. Sunkara G, Kompella UB. Membrane transport processes in the eye. In: Mitra AK, ed. Ophthalmic drug delivery systems. New York (NY): Marcel Dekker Inc.; 2003:13-58.
21. Mahmood A, Bonengel S, Laffleur F, et al. Can thiolation render a low molecular weight polymer of just 20-kDa mucoadhesive? Drug Dev Ind Pharm 2015. [Epub ahead of print]. DOI: 10.3109/03639045.2015.1061538.
22. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 1982;26:207-18.
23. ASHP technical assistance bulletin on pharmacy-prepared ophthalmic products. American Society of Hospital Pharmacists. Am J Hosp Pharm 1993;50:1462-3.
24. Ali Y, Lehmussaari K. Industrial perspective in ocular drug delivery. Adv Drug Deliv Rev 2006;58:1258-68.
25. DB-ALM, MTT Assay-Summary Method. Available from: http://ecvam-dbalm.jrc.ec.europa.eu/ [last accessed 26 Aug 2015].
26. Almeida H, Amaral MH, Lobão P, Lobo JM. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today 2014;19:400-12.
27. Gyarmati B, Vajna B, Némethy Á, et al. Redox- and pHresponsive cysteamine-modified poly(aspartic acid) showing a reversible sol-gel transition. Macromol Biosci 2013;13:633-40.
28. Gyarmati B, Krisch E, Szilágyi A. In situ oxidation-induced gelation of poly(aspartic acid) thiomers. React Funct Polym 2014;84:29-36.
29. Operating manual OCA (OCA 5, OCA 10, OCA 15, OCA 15 plus, OCA 20, OCA 30, OCAH 200 and OCAH 230) Dataphysics (2002) 71.
30. Sandri G, Bonferoni MC, Rossi S, et al. Thermosensitive eyedrops containing platelet lysate for the treatment of corneal ulcers. Int J Pharm 2012;426:1-6.
31. Mori M, Rossi S, Bonferoni MC, et al. Calcium alginate particles for the combined delivery of platelet lysate and vancomycin hydrochloride in chronic skin ulcers. Int J Pharm 2014;461:505-13.
32. Salcedo I, Sandri G, Aguzzi C, et al. Intestinal permeability of oxytetracycline from chitosan-montmorillonite nanocomposites. Colloids Surf B Biointerfaces 2014;117:441-8.
33. Patel S, Boyd KE, Burns J. Age, stability of the precorneal tear film and the refractive index of tears. Cont Lens Anterior Eye 2000;23:44-7.
34. Yañez-Soto B, Mannis MJ, Schwab IR, et al. Interfacial phenomena and the ocular surface. Ocul Surf 2014;12:178-201.
35. Ziemssen F, Zierhut M. Principles of therapy. In: Fraunfelder FT, Fraunfelder FW, Chambers WA, eds. Clinical ocular toxicology. Drugs, chemicals and herbs. Philadelphia (PA): Saunders Elsevier; 2008:1-7.
36. Januleviciene I, Siaudvytyte L, Barsauskaite R. Ophthalmic drug delivery in glaucoma - a review. Pharmaceutics 2012;4:243-51.
37. Pallas NR, Harrison Y. An automated drop shape apparatus and the surface tension of pure water. Colloids Surf 1990;43:169-94.
38. Taylor S, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther 2002;18:401-9.
39. Lafuma A, Robert J, Berdeaux G. Ocular discomfort, compliance and intra-ocular pressure (IOP) control in patients treated for glaucoma. Value Health 2011;14:A502 (IGR:13-4).
40. Fraunfelder FT. Ocular drug delivery and toxicology. In: Fraunfelder FT, Fraunfelder FW, Chambers WA, eds. Clinical ocular toxicology. Drugs, chemicals and herbs. Philadelphia (PA): Saunders Elsevier; 2008:9-14.
41. Vian L, Vincent J, Maurin J, et al. Comparison of three in vitro cytotoxicity assays for estimating surfactant ocular irritation. Toxicol In Vitro 1995;9:185-90.
42. Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm 2009;71:505-18.
43. Saettone MF, Giannaccini B, Guiducci A, et al. Polymer effects on ocular bioavailability. II. The influence of benzalkonium chloride on the mydriatic response of tropicamide in different polymeric vehicles. Int J Pharm 1985;25:73-83.
44. Asane GS, Nirmal SA, Rasal KB, et al. Polymers for mucoadhesive drug delivery system: a current status. Drug Dev Ind Pharm 2008;34:1246-66.
45. Millotti G, Vetter A, Leithner K, et al. Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide. Drug Dev Ind Pharm 2014;40:1677-82.
46. Robinson JR, Mlynek GM. Bioadhesive and phase-change polymers for ocular drug delivery. Adv Drug Deliv Rev 1995;16:45-50.